Show simple item record

dc.contributor.authorClapper, Erin
dc.contributor.authorWang, Sicong
dc.contributor.authorRaninga, Prahlad V
dc.contributor.authorDi Trapani, Giovanna
dc.contributor.authorTonissen, Kathryn F
dc.date.accessioned2020-03-12T03:14:07Z
dc.date.available2020-03-12T03:14:07Z
dc.date.issued2020
dc.identifier.issn2076-3921
dc.identifier.doi10.3390/antiox9030207
dc.identifier.urihttp://hdl.handle.net/10072/392291
dc.description.abstractChronic myeloid leukaemia (CML) is currently treated with inhibitors of the CML specific oncoprotein, bcr-abl. While this strategy is initially successful, drug resistance can become a problem. Therefore, new targets need to be identified to ensure the disease can be appropriately managed. The thioredoxin (Trx) system, comprised of Trx, thioredoxin reductase (TrxR), and NADPH, is an antioxidant system previously identified as a target for therapies aimed at overcoming drug resistance in other cancers. We assessed the effectiveness of TrxR inhibitors on drug resistant CML cells and examined links between TrxR and the bcr-abl cell-signalling pathway. Two TrxR inhibitors, auranofin and [Au(d2pype)2]Cl, increased intracellular ROS levels and elicited apoptosis in both sensitive and imatinib resistant CML cells. Inhibition of TrxR activity by these pharmacological inhibitors, or by specific siRNA, also resulted in decreased bcr-abl mRNA and protein levels, and lower bcr-abl downstream signalling activity, potentially enhancing the effectiveness of TrxR inhibitors as CML therapies. In addition, imatinib resistant CML cell lines showed upregulated expression of the Trx system. Furthermore, analysis of datasets showed that CML patients who did not respond to imatinib had higher Trx mRNA levels than patients who responded to treatment. Our study demonstrates a link between the Trx system and the bcr-abl protein and highlights the therapeutic potential of targeting the Trx system to improve CML patients' outcomes.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.ispartofpagefrom207:1
dc.relation.ispartofpageto207:18
dc.relation.ispartofissue3
dc.relation.ispartofjournalAntioxidants
dc.relation.ispartofvolume9
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchcode11
dc.subject.keywordsCML
dc.subject.keywordsROS
dc.subject.keywordsapoptosis
dc.subject.keywordsbcr-abl
dc.subject.keywordsdrug resistance
dc.titleCross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationClapper, E; Wang, S; Raninga, PV; Di Trapani, G; Tonissen, KF, Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment., Antioxidants, 2020, 9 (3), pp. 207:1-207:18
dcterms.dateAccepted2020-03-01
dcterms.licensehttp://creativecommons.org/licenses/by/4.0/
dc.date.updated2020-03-11T22:31:45Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
gro.hasfulltextFull Text
gro.griffith.authorTonissen, Kathryn F.
gro.griffith.authorDi Trapani, Jenny
gro.griffith.authorWang, Sicong
gro.griffith.authorRaninga, Prahlad V.
gro.griffith.authorClapper, Erin M.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record